Shitanshu Uppal

Prof. of Gyn Oncology, Division Director #UmichGynOnc. Part of the @MOQCteam. @MichiganRoss Alum. Founder of @gyoedu

[Shitanshu Uppal @uppals]

For those graduating from fellowship/residency this year; training is tough and difficult.
As you get ready to take on your new role, consider this quote from Will Durant -

“Those who have suffered much become very bitter or very gentle.”

I urge you to consider the latter!

[gyoedu @gyoedu]

Launching https://t.co/s8PLOffPzo

Enhance patient preparedness and adherence by providing accessible, standardized chemotherapy educational videos in the clinic.

Minimize staff administrative time and ensure all patients receive consistent pre-treatment instruction.

[Shitanshu Uppal @uppals]

@JeffDeloose @PipeCabreraV @pferrada1 @TomVargheseJr @CiruAndes2 Stratafix is our next study to see if hernia + ssi is lower … love this suture

[Shitanshu Uppal @uppals]

@BillzamMD But in dMMR - I can see the QOL better with cancer response. Agree with earlier tweet

[Shitanshu Uppal @uppals]

@BillzamMD Shit scales measuring QOL. I have not seen a single pharma led study where QOL is worse.
But better QOL is a new finding.
In reality, we are finding that immune toxicity is much worse than reported in trials. Use of IO in pMMR and p53abn patient is not a great use of resources

[Shitanshu Uppal @uppals]

@marklewismd Tried to prescribe it - got a denial for the prior auth 🥸

[Shitanshu Uppal @uppals]

Is it ok to cry when your patient progresses or has a recurrence? Is it ok to cry when facilitating end of life discussions? And how does that impact oncologist self perception and worth? Our poster in #ASCO2025 presented by amazing med student Hannah Catzen
#burnout

[gyoedu @gyoedu]

Most benefit in stage III pts (n=468):
PCS vs NACT/ICS
• PFS: 26.3 vs 21.4 mos
• OS: 63.7 vs 53.2 mos
Surgical quality mattered—complete resection = median OS of 67 mos.
PCS offers long-term survival advantage in resectable, non-frail pts. #gyncsm #ovariancancer

[gyoedu @gyoedu]

TRUST trial: In non-frail pts with stage IIIB-IVB ovarian cancer, PCS led to longer PFS (22.2 vs 19.7 mos, p=0.02) vs NACT/ICS. OS favored PCS (54.3 vs 48.3 mos, p=0.24), esp. in stage III pts (OS: 63.7 vs 53.2 mos). PCS remains standard in expert centers. #gyncsm #oncology @sgo

[Shitanshu Uppal @uppals]

@oncology_bg I put my money in the ATOMIC trial 😂

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival.
Perfect case example of a #cancergroundshot trial.

https://t.co/ZnqeplJ7IA

[Shitanshu Uppal @uppals]

@oncology_bg Looking forward to you talk @oncology_bg

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Hello Michigan!
I’ll be in Ann Arbor next Thursday to discuss critical appraisal of cancer drug RCTs using the CSO checklist.
Do drop by if you’re around (or by zoom).
Perfect timing to get you all prepared for #ASCO25.

[gyoedu @gyoedu]

A new perspective on how to think about primary debulking surgery vs. neoadjuvant.

Two articles discussed:
Jochum F, Dumas É, Gougis P, et al. Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation. Am J Obstet Gynecol. 2025;232(2):194.e1-194.e11.

Shachar E, Raz Y, Rotkop G, et al. Cytoreductive surgery in advanced epithelial ovarian cancer: a real-world analysis guided by clinical variables, homologous recombination, and BRCA status. Int J Gynecol Cancer. 2025;35(6):101809.

[gyoedu @gyoedu]

👩‍⚕️ Residents: jump-start your #GynOnc basics with our #BlackboardMethod—fast, chalk-style sessions that turn complex cases into clear takeaways. Start with this quick video on Non-Epithelial Ovarian Tumors and level up your learning ➡️
Visit https://t.co/1bjM0bQdxP for more videos and quizzes!!

[Shitanshu Uppal @uppals]

@leitaomd @IJGConline @AngelesSecord @dukeobgyn @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 I don’t disagree with you but the reality is that sequencing is now happening for every patient whether it makes OS better or not!
Even worse, sometimes the same patient is getting the tumor testing several times 😕 - and in some cases having to pay out of pocket

[gyoedu @gyoedu]

Resident assessment quiz on https://t.co/ZdldCP98aF

https://t.co/8p9UgCYejU
Give it a try!
#match2025 #obgynresidents #gynonc

[Shitanshu Uppal @uppals]

#strangerthings night sky in ⁦@AnnArbor⁩

[gyoedu @gyoedu]

Learn the basics of Gynecology Oncology to do well in your Gynecology Oncology Rotation https://t.co/h1xeOecnIU
Now, with QUIZZES built into the lessons.
#obgynresident #gynonc #match2025

[gyoedu @gyoedu]

Basics of Gynecology Oncology Course for the residents - Now with quizzes #ObgynMatch https://t.co/h1xeOecnIU